Surface Oncology to Participate in Upcoming March Investor Conferences

Rhea-AI Summary

Surface Oncology (Nasdaq: SURF) announced that Dr. Rob Ross, the incoming CEO, will present at two upcoming virtual investor conferences. The Cowen 41st Annual Healthcare Conference is scheduled for March 1, 2021, at 10:20 a.m. ET, while the H.C. Wainwright Global Life Sciences Conference will take place on March 9-10, 2021, with a presentation recording available during the event. The presentations will highlight Surface’s lead programs, including SRF617 and SRF388, and their preclinical program SRF114.

CAMBRIDGE, Mass., Feb. 24, 2021 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation therapies targeting the tumor microenvironment, today announced that Rob Ross, M.D., incoming chief executive officer, will participate in the following virtual investor conferences:

• Cowen 41^st Annual Healthcare Conference, Monday, March 1, 2021, at 10:20 a.m. ET as part of the Novel IO panel.
  
  
• H.C. Wainwright Global Life Sciences Conference, March 9-10, 2021, presentation recording will be available to investors during the course of the conference.
  

The presentations will focus on Surface’s lead programs, SRF617 (targeting CD39) and SRF388 (targeting IL-27), as well as Surface’s emerging pre-clinical program, SRF114 (targeting CCR8).

About Surface Oncology:

Surface Oncology is an immuno-oncology company developing next-generation antibody therapies focused on the tumor microenvironment. Its pipeline includes two wholly-owned clinical-stage programs targeting CD39 (SRF617) and IL-27 (SRF388), as well as a preclinical program focused on depleting regulatory T cells via targeting CCR8 (SRF114). In addition, Surface has two partnerships with major pharmaceutical companies: a collaboration with Novartis targeting CD73 (NZV930; Phase 1) and a collaboration with GlaxoSmithKline targeting PVRIG (SRF813; preclinical). Surface’s novel cancer immunotherapies are designed to achieve a clinically meaningful and sustained anti-tumor response and may be used alone or in combination with other therapies. For more information, please visit www.surfaceoncology.com.

Contacts:

Investors
Matt Lane
matt@gilmartinir.com
617-901-7698

Media
Matthew Corcoran
mcorcoran@tenbridgecommunications.com
617-866-7350

FAQ

What is the schedule for Surface Oncology's virtual investor conferences in March 2021?

Surface Oncology will present at the Cowen 41st Annual Healthcare Conference on March 1, 2021, at 10:20 a.m. ET and at the H.C. Wainwright Global Life Sciences Conference on March 9-10, 2021.

What programs will be highlighted in Surface Oncology's presentations?

The presentations will focus on Surface's lead programs, SRF617, targeting CD39; SRF388, targeting IL-27; and their preclinical program SRF114, targeting CCR8.

Who is the incoming CEO of Surface Oncology?

Dr. Rob Ross is the incoming CEO of Surface Oncology.

What is the focus of Surface Oncology's drug development?

Surface Oncology develops next-generation immuno-oncology therapies targeting the tumor microenvironment.

Where can I find more information about Surface Oncology?

More information about Surface Oncology can be found on their website at www.surfaceoncology.com.